Table 1. Baseline characteristics of patients.
| covariate | classification | frequency |
|---|---|---|
| Menopausal status | Pre-menopause | 68.65%(n = 127) |
| Menopause | 31.35%(n = 58) | |
| Tumor T | T1 | 22.16%(n = 41) |
| T2 | 52.43%(n = 97) | |
| T3 | 14.59%(n = 27) | |
| T4 | 8.65%(n = 16) | |
| Tx | 2.16(n = 4) | |
| Lymph node involvement | N0 | 34.59%(n = 64) |
| N1 | 31.35%(n = 58) | |
| N2 | 16.76%(n = 31) | |
| N3 | 9.73%(n = 18) | |
| Nx | 7.57%(n = 14) | |
| Distant metastasis | M0 | 89.19%(n = 165) |
| M1 | 10.81%(n = 20) | |
| stage | 1 | 12.97%(n = 24) |
| 2 | 48.11%(n = 89) | |
| 3 | 28.11%(n = 52) | |
| 4 | 10.81%(n = 20) | |
| Pathologic grade | 1 | 2.70%(n = 5) |
| 2 | 77.84%(n = 144) | |
| 3 | 19.46%(n = 36) | |
| Estrogen receptor | Positive | 66.49%(n = 123) |
| Negative | 33.51%(n = 62) | |
| Progesterone receptor | Positive | 61.62%(n = 114) |
| Negative | 38.38%(n = 71) | |
| HER2/neu | Positive | 23.24%(n = 43) |
| Negative | 76.76%(n = 142) | |
| Surgery type | MRM* | 76.22%(n = 141) |
| BCS* | 15.14%(n = 28) | |
| Biopsy only | 8.65%(n = 16) | |
| Relapse | No recurrence | 71.89%(n = 133) |
| Local recurrence | 4.86%(n = 9) | |
| Distant recurrence | 12.97%(n = 24) | |
| N/A** | 10.27%(n = 19) | |
| Treatment | Chemotherapy | 97.39%(n = 182) |
| Radiotherapy | 68.11%(n = 126) | |
| Hormone therapy | 64.32%(n = 119) | |
| P53 | Positive | 35.14%(n = 65) |
| Negative | 64.86%(n = 120) |
*MRM: modified radical mastectomy, BCS: breast conserving surgery.
**Patients with an advanced metastatic disease from the time of diagnosis.